Outcomes of Oral Vinorelbine in Progressive Desmoid Fibromatosis-Response.

Mir, Olivier; Honoré, Charles; Chamseddine, Ali N; Faron, Matthieu; Haddag-Miliani, Leila; Bayle, Arnaud; Le Cesne, Axel

Mir, Olivier; Honoré, Charles; Chamseddine, Ali N; Faron, Matthieu; Haddag-Miliani, Leila; Bayle, Arnaud; Le Cesne, Axel.

Afiliação

Mir O; Department of Ambulatory Cancer Care, Gustave Roussy Cancer Institute, Villejuif, France. olivier.mir@gustaveroussy.fr.
Honoré C; Department of Surgery, Gustave Roussy Cancer Institute, Villejuif, France.
Chamseddine AN; Department of International Patients Care, Gustave Roussy Cancer Institute, Villejuif, France.
Faron M; Department of Surgery, Gustave Roussy Cancer Institute, Villejuif, France.
Haddag-Miliani L; Department of Medical Imaging, Gustave Roussy Cancer Institute, Villejuif, France.
Bayle A; Department of Ambulatory Cancer Care, Gustave Roussy Cancer Institute, Villejuif, France.
Le Cesne A; Department of International Patients Care, Gustave Roussy Cancer Institute, Villejuif, France.

Clin Cancer Res ; 27(7): 2120, 2021 04 01.

Article em En | MEDLINE | ID: mdl-33795374

Assuntos

Fibromatose Agressiva; Protocolos de Quimioterapia Combinada Antineoplásica; Fibromatose Agressiva/tratamento farmacológico; Humanos; Vinorelbina/uso terapêutico

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fibromatose Agressiva Limite: Humans Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: França

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google